Healthcare Analysts discuss emerging therapies in chronic myeloid leukemia (CML), (relevant companies NVS, ENLV, TERN, TAK, BMY, PFE) on an Analyst/Industry conference call to be held on October 31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Novartis presents new Pluvicto data, showed improvement in rPFS